Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Astrazeneca (AZNCF) over the last 15 years, with Q1 2025 value amounting to -$265.0 million.

  • Astrazeneca's Non Operating Income rose 1225.17% to -$265.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.4 billion, marking a year-over-year increase of 17463.01%. This contributed to the annual value of $1.3 billion for FY2025, which is 389.41% up from last year.
  • Latest data reveals that Astrazeneca reported Non Operating Income of -$265.0 million as of Q1 2025, which was up 1225.17% from $2.2 billion recorded in Q4 2024.
  • Astrazeneca's Non Operating Income's 5-year high stood at $2.2 billion during Q4 2024, with a 5-year trough of -$945.0 million in Q4 2023.
  • For the 5-year period, Astrazeneca's Non Operating Income averaged around -$84.8 million, with its median value being -$287.0 million (2023).
  • As far as peak fluctuations go, Astrazeneca's Non Operating Income plummeted by 1272.08% in 2022, and later surged by 33312.17% in 2024.
  • Astrazeneca's Non Operating Income (Quarter) stood at -$283.0 million in 2021, then decreased by 12.72% to -$319.0 million in 2022, then plummeted by 196.24% to -$945.0 million in 2023, then soared by 333.12% to $2.2 billion in 2024, then tumbled by 112.03% to -$265.0 million in 2025.
  • Its Non Operating Income was -$265.0 million in Q1 2025, compared to $2.2 billion in Q4 2024 and -$274.0 million in Q3 2024.